Published in Carcinogenesis on May 16, 2008
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03
Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res (2012) 1.85
SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene (2012) 1.70
Retracted Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene (2008) 1.59
Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies. Transl Psychiatry (2015) 1.49
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene (2016) 0.97
Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer (2009) 0.95
Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol (2011) 0.91
Brg-1 targeting of novel miR550a-5p/RNF43/Wnt signaling axis regulates colorectal cancer metastasis. Oncogene (2015) 0.91
Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene (2011) 0.86
Prohibitin is required for transcriptional repression by the WT1-BASP1 complex. Oncogene (2013) 0.84
Chromosome Y genetic variants: impact in animal models and on human disease. Physiol Genomics (2015) 0.80
The Ric-8B gene is highly expressed in proliferating preosteoblastic cells and downregulated during osteoblast differentiation in a SWI/SNF- and C/EBPbeta-mediated manner. Mol Cell Biol (2011) 0.80
Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1. Mol Cancer (2010) 0.76
Prohibitin promotes androgen receptor activation in ER-positive breast cancer. Cell Cycle (2017) 0.75
BRG1 targeting STAT3/VEGFC signaling regulates lymphangiogenesis in colorectal cancer. Oncotarget (2016) 0.75
Use of biotinylated plasmid DNA as a surrogate for HSV DNA to identify proteins that repress or activate viral gene expression. Proc Natl Acad Sci U S A (2012) 0.75
Extensive cargo identification reveals distinct biological roles of the 12 importin pathways. Elife (2017) 0.75
The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells. Oncogenesis (2017) 0.75
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 8.99
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 8.72
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Role of CBP/P300 in nuclear receptor signalling. Nature (1996) 7.36
Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 6.15
Cancer statistics, 1994. CA Cancer J Clin (1994) 4.14
Androgen receptor (AR) coregulators: an overview. Endocr Rev (2002) 4.01
Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (1988) 3.96
Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell (2006) 3.12
Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev (2001) 3.09
Generation of superhelical torsion by ATP-dependent chromatin remodeling activities. Cell (2000) 2.95
Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state. Cell (1998) 2.63
Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene (2002) 2.23
The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem (2004) 2.15
Functional selectivity of recombinant mammalian SWI/SNF subunits. Genes Dev (2000) 2.07
Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J (2002) 2.02
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol (2000) 1.80
Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene (1999) 1.78
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. Mol Cell Biol (2000) 1.66
Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem (2002) 1.56
The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am (1999) 1.55
Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol Cell Biol (1999) 1.55
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor tau1 activation domain. Mol Cell Biol (2000) 1.39
Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol (2006) 1.38
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev (2006) 1.35
Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J (2002) 1.34
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J (2004) 1.29
Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol (2006) 1.28
Androgen receptor corepressors: an overview. Prostate (2005) 1.25
Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem (2003) 1.23
Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene (2004) 1.16
Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis. Oncogene (2002) 1.15
Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Ther (2006) 1.13
Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene (2006) 1.11
Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene (2007) 1.08
A putative coiled-coil domain of prohibitin is sufficient to repress E2F1-mediated transcription and induce apoptosis. Biochem Biophys Res Commun (2003) 1.08
Nucleosome remodeling by the human SWI/SNF complex requires transient global disruption of histone-DNA interactions. Mol Cell Biol (2002) 1.07
The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate (2006) 0.90
Medical therapy of prostate cancer. A review. Minerva Urol Nefrol (2005) 0.84
The androgen receptor: structure, mutations, and antiandrogens. Cancer Invest (2003) 0.84
Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer. Expert Rev Anticancer Ther (2006) 0.79
Fetal hemoglobin in sickle cell anemia. Blood (2011) 2.44
Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res (2006) 1.64
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
Retracted HIC1 regulates tumor cell responses to endocrine therapies. Mol Endocrinol (2009) 1.42
Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J (2005) 1.38
Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J (2002) 1.34
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J (2004) 1.29
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood (2002) 1.26
Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. Am J Hematol (2011) 1.26
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res (2011) 1.15
Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood (2006) 1.15
Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets (2003) 1.10
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood (2011) 1.09
Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer (2009) 1.08
Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem (2006) 1.08
Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Cancer Biol Ther (2007) 1.05
Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem (2002) 1.05
Protein kinase C delta is required for survival of cells expressing activated p21RAS. J Biol Chem (2007) 1.04
Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. Cell Growth Differ (2002) 1.03
Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis (2005) 1.03
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate (2012) 1.00
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors. Endocr Relat Cancer (2011) 0.97
Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci (2010) 0.95
Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol (2009) 0.94
Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol (2009) 0.93
Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics (2008) 0.93
Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo. BMC Cancer (2014) 0.91
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology (2002) 0.91
Drosophila female sterile (1) homeotic is a multifunctional transcriptional regulator that is modulated by Ras signaling. Dev Dyn (2008) 0.91
Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett (2007) 0.91
Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs (2008) 0.90
Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther (2007) 0.90
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol (2005) 0.90
Butyrate histone deacetylase inhibitors. Biores Open Access (2012) 0.90
Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. Adv Virol (2012) 0.89
T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides (2011) 0.89
PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1. Cell Signal (2008) 0.89
Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol (2003) 0.87
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol (2010) 0.87
Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem Biol Drug Des (2006) 0.86
Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol (2012) 0.86
Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo. Blood Cells Mol Dis (2011) 0.85
The societal cost of schizophrenia in Sweden. J Ment Health Policy Econ (2013) 0.84
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication. Virology (2003) 0.84
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) (2010) 0.83
Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism. Virology (2005) 0.83
The societal cost of bipolar disorder in Sweden. Soc Psychiatry Psychiatr Epidemiol (2013) 0.83
Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis (2006) 0.82
Desensitization of the PDGFbeta receptor by modulation of the cytoskeleton: the role of p21(Ras) and Rho family GTPases. Exp Cell Res (2002) 0.81
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. J Clin Pharmacol (2011) 0.81
Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. J Cell Physiol (2004) 0.80
Identification of LTR-specific small non-coding RNA in FeLV infected cells. FEBS Lett (2009) 0.80
Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells. Nucleic Acid Ther (2013) 0.79
Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol (2014) 0.79
Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics (2008) 0.78
Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis. Nucleic Acid Ther (2013) 0.78
The role of Ras in T lymphocyte activation. Cell Signal (2002) 0.78
[Costs of bipolar disorder, depression, schizophrenia and anxiety. The right treatments can have significant positive socio-economic effects]. Lakartidningen (2014) 0.78
Fas ligand-mediated lethal hepatitis after rapid lysis of a localized natural killer cell lymphoma. Clin Lymphoma Myeloma (2006) 0.78
Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Anticancer Res (2008) 0.77
Differences in health and health behaviors between state employees and other employed adults in Oregon, 2007. Prev Chronic Dis (2010) 0.75
Genetic studies of fetal hemoglobin in the Arab-Indian haplotype sickle cell-β(0) thalassemia. Am J Hematol (2013) 0.75
Hematology clinic. Sickle cell disease. Hematology (2014) 0.75
[The generics reform lowered drug prices]. Lakartidningen (2007) 0.75
Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. Laryngoscope (2002) 0.75